Mar 21st 2013 - Edison Investment Research today published a report on Sunesis Pharmaceuticals entitled "Countdown To The VALOR Result". In summary, the report says:
Sunesis’s investment case critically depends entirely on the outcome – due in around 12 months – of the VALOR study of vosaroxin in relapsed/refractory acute myeloid leukaemia. This study has enrolled 563 (83%) of its target 675 patients and expectations for success are already high following last year’s cohort expansion. This considerably increases the probability of vosaroxin showing a survival advantage to the statistical standard. We already assume a high probability of success in our rNPV, which yields a value of $436m or $8.46 per share (basic) or $6.98 (fully diluted).
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »